Research
Hormonal
Peripheral administration of Glucagon-like peptide-1 (GLP-1) reduces food intake in a dose-dependent manner in both normal weight and obese subjects, although obese subjects have a blunted postprandial GLP-1 response.
GLP-1 reduces food intake in both lean and obese people. However, obese people have a blunted natural response. Pharmacological GLP-1 agonists (like exenatide and liraglutide) are designed to overcome this by being resistant to degradation and providing a stronger signal.
GoodQualifiesHIGH confidence
Intravenous infusion of GLP-1 results in a dose-dependent reduction in food intake in both normal weight and obese subjects [98] although obese subjects have a blunted postprandial GLP-1 response compared to lean subjects [94].
Why this rating
The paper cites studies showing dose-dependent reduction in food intake, but also notes the blunted response in obesity.
Source
The role of gut hormones and the hypothalamus in appetite regulation
Keisuke Suzuki et al. · Endocrine Journal · 2010
DOI 10.1507/endocrj.k10e-077
narrative_reviewCited 315×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Peripheral administration of Peptide YY (PYY) (3-36) reduces food intake and body weight gain in rodents and reduces appetite in humans, primarily by acting on Y2 receptors in the arcuate nucleus and via vagal afferent signaling.Good
- Gastric bypass surgery leads to sustained weight loss, partly mediated by a decrease in circulating ghrelin and an increase in peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →